Aerium Therapeutics
Pharmaceutical ManufacturingMassachusetts, United States11-50 Employees
Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.
Innovative Antiviral Focus Aerium's commitment to discovering antibodies and small molecule antivirals for SARS-CoV-2 and other epidemic threats presents opportunities to partner in vaccine research, diagnostic tools, and complementary antiviral solutions.
Recent Portfolio Expansion The development of three monoclonal antibodies targeting predominant SARS-CoV-2 variants indicates ongoing innovation; engaging with their R&D team could open avenues for collaboration on next-generation therapies.
Funding & Growth Potential With Series A funding from notable investors like Omega Funds and F-Prime Capital and annual revenues between 1M and 10M, Aerium is positioned for growth, making it a strategic partner for pharmaceutical supply chain, manufacturing, and clinical support services.
Technology-Driven Development Utilizing cloud platforms like Google Cloud and productivity tools such as Microsoft 365, Aerium emphasizes digital infrastructure which can facilitate innovative tech collaborations, data sharing, and streamlined project management.
Aerium Therapeutics uses 8 technology products and services including Microsoft 365, Font Awesome, Google Cloud, and more. Explore Aerium Therapeutics's tech stack below.
| Aerium Therapeutics Email Formats | Percentage |
| First.Last@aeriumtx.com | 47% |
| First@aeriumtx.com | 3% |
| First.Middle@aeriumtx.com | 3% |
| First.Last@aeriumtx.com | 47% |
Pharmaceutical ManufacturingMassachusetts, United States11-50 Employees
Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.
Aerium Therapeutics's revenue is estimated to be in the range of $1M$10M
Aerium Therapeutics's revenue is estimated to be in the range of $1M$10M